Kanser ya prostate yili yamuchiali ha kansa yize yakupwa chinji kuli malunga hashi heswe, ni unji wa 1,276 a tununu ja atu waze ayijile ha mwaka 2018, yize yakulinga 7.1% ha kansere eswe kuli malunga.
Uhashi wa kufwa ha mukaka wa prostate uli unji chinji, ni unji wa 37,005 wa kufwa hashi heswe ha mwaka 2018.
Chipwe chocho, kufwa chacho chinalisa chinji kuli yifuchi yeswe, ni kusulo ya Africa che chano chilemu chinji ha kufwa cha kansa ya prostate hano hashi, alioze Nigeria che chilemu chinji ku chifuchi chacho.
Mu Nigeria, kansa ya prostate yili kansa yize yakupwa ni malunga anji, ni kufwa chinji, ni unji wa 32.8 ha 100,000 ja malunga.
Chino chili unji wa kufwa kuhiana ku Norte de América.
Kunyingika chishina chacho muze hichili, kukamba mbongo ja kuhengula ni kunyingika, ni kuhona kusoneka kanawa ni kuhana sango jacho chakukwasa chinji kufwa cha atu mu Nigeria.
Mu Estados Unidos, kansa ya prostate yili chitela chamuchiali cha kufwa ha mukaka ha malunga, ni unji wa 40,0000 a malunga akufwa ha mukaka ha mwaka.
Uhashi wa kufwa ha mukaka wa prostate unakehe-kenhe chize ha miaka ya 1990, alioze nihindu uchili ni ulemu unji ku mwono wa atu.
Musongo wa prostate unashiha chinji atu, chinji-chiwe mu yifuchi yize keshi yitumbo yipema ya uhayele.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Ulemu: ukwaso wa yikola']
['Site yino kayitela hanga atu anyingike hakutwala ku yikola ni yikuma yikwo, kuyishi ni yiyulo ya mandotolo.']
['Tala ha makina yize yakukwasa hanga uwane kumbululo lia yihula, hi yikalu ko muze anavuluka unji wa atu waze ali ni yikola.']
['Teta mashimbu eswe kuwana yiyulo ya ndotolo we hanji umwe mukwa-kuhana yiyulo ya uhayele ha chikuma cha yikola. Kanda ulionga yiyulo ya ndotolo hanji kutohwesa kuyitanga ha mukunda wa yimwe yuma yize watanga ha site yino. Nyi wanyonga ngwo uli ni mulonga wa uhayele, shinga 911 hanji yako ha chipatulo cha usopeso chize chili hakamwihi. Kukushi usepa wa ndotolo ni ndotolo uze wakunjila ha site yino hanji ha kuzachisa site yino. Chipwe BioMedLib hanji akwa-kukalakala nayo, hanji yoze wakukwasa ha site yino, keshi kulinga nichimwe, chipwe kusolola, hakutwala ku sango jize jili ha site yino hanji ha kuzachisa site yino.']
['Uhashi wa akwa-kusoneka']
['Shimbi ya Digital Millennium Copyright Act ya 1998, 17 U.S.C. § 512 (DMCA) yinambe ngwo, waze ali ni shimbi ja akwa-kusoneka waze anafuliela ngwo yuma yize yili ha Internet yinapinjisa shimbi ja akwa-kusoneka ja mu Estados Unidos. ']
['Nyi unafuliela ni mbunge yeswe ngwo yikuma yeswe yize akuzachisa ha site yino yinapinjisa shimbi ja akwa-kusoneka, yena (mba yoze wakuzachisa) muhasa kututumina mukanda hanga ututuhwise yikuma yacho hanji kuhona kuyimona.']
['Sango jacho katamba kujituma ha mukanda ha email (tala ha chihanda cha "Contact" ha email).']
['Shimbi ya DMCA yinambe ngwo, sango je ha yize akuhanjika ngwo yapinjisa shimbi ja akwa-kusoneka yili ni sango jacho: (1) kulumbununa mulimo uze uli ni shimbi ja akwa-kusoneka uze anazangamisa; (2) kulumbununa yikuma yize anazangamisa ni sango jize jinahase kutukwasa hanga tuwane yikuma yacho; (3) kulweza yoze mutuhasa kumuheta, ngwe adresi, numero ya telefone ni email; (4) maliji waze yena musolola ngwo, yuma yize anazangamisa kuyishi ni utayizo wa mwene wa shimbi ja akwa-kusoneka, hanji yoze akuzachisa, hanji ni shimbi jize anazangamisa; ']
['(5) Sango jize yena musoneka, ni shimbi jize makahana, ngwo sango jize jili ha mukanda jili ja umwenemwene nawa uli ni ulite wakukwasa hanga akwa-kusoneka afunge shimbi jize anakwambulula ngwo jinalitepulula;']
['nawa (6) chijimbikilo cha mwata wa shindakenyo ya ulite wa yuma hanji cha muthu yoze uli ni ulite wa kulinga yuma ha jina lia mwata wa shindakenyo ya yuma.']
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Hakutwala ku']
['BioMedLib kakuzachisa makina hanga ahase kuhula ni kukumbulula.']
['Mutuputuka ni 35 a tununu ja mikanda ya PubMed/Medline. nawa ni mikanda ya RefinedWeb.']
